 Prospective, randomised study: Effect of mycophenolatmofetil MMF and CNI withdrawal in patients with histologically proven chronic allograft nephropathy Indication: change in immunosuppressive treatment of chronic allograft nephropathy CANafter renal transplantation Hypothesis: Antimetabolite MMF is able to stop progression of CAN and improve blood pressure metabolic parameters and structural vessel wall changes 